HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Trans-Tenon's retrobulbar triamcinolone acetonide injection for macular oedema related to branch retinal vein occlusion.

AbstractBACKGROUND:
The aim of the study was to evaluate the safety and effectiveness of trans-Tenon's retrobulbar triamcinolone acetonide (TA) injection for macular oedema associated with branch retinal vein occlusion (BRVO).
METHODS:
We reviewed the medical records of 50 consecutive patients with macular oedema associated with BRVO who were treated with trans-Tenon's retrobulbar TA injection (20 mg) as initial treatment for a follow-up period of at least 12 months. Foveal thickness determined by optical coherence tomography, visual acuity, intraocular pressure (IOP) and cataract progression were measured.
RESULTS:
The mean duration between oedema onset and TA injection was 4.9 months. Foveal thickness decreased significantly at 3 months after injection (p<0.0001). Furthermore, the percentage reduction in foveal thickness in eyes with posterior vitreous detachment (PVD; n = 23) was significantly greater than that without PVD (n = 27, p = 0.003). Improved visual acuity by at least 0.20 log minimum angle of resolution (logMAR) was seen in 22 eyes (44%; 11 eyes with PVD and 11 eyes without PVD). After completion of the 3-month follow-up, 29 eyes (58%) needed additional treatment including TA injections or pars plana vitrectomy (PPV). PPV seemed to be effective for macular oedema resistant to TA. IOP elevation and cataract progression occurred in less than 10% of all patients.
CONCLUSIONS:
Trans-Tenon's retrobulbar TA injection appeared safe and relatively effective for macular oedema associated with BRVO. In eyes resistant to TA injection, PPV may be effective as an adjunctive treatment.
AuthorsT Kawaji, A Takano, Y Inomata, N Sagara, K Iwao, M Inatani, M Fukushima, H Tanihara
JournalThe British journal of ophthalmology (Br J Ophthalmol) Vol. 92 Issue 1 Pg. 81-3 (Jan 2008) ISSN: 1468-2079 [Electronic] England
PMID17965103 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Glucocorticoids
  • Triamcinolone Acetonide
Topics
  • Aged
  • Aged, 80 and over
  • Cataract (pathology)
  • Disease Progression
  • Drug Evaluation
  • Female
  • Follow-Up Studies
  • Fovea Centralis (pathology)
  • Glucocorticoids (adverse effects, therapeutic use)
  • Humans
  • Macular Edema (drug therapy, etiology, pathology, physiopathology)
  • Male
  • Middle Aged
  • Ocular Hypertension (chemically induced)
  • Retinal Vein Occlusion (complications)
  • Retrospective Studies
  • Treatment Outcome
  • Triamcinolone Acetonide (adverse effects, therapeutic use)
  • Visual Acuity (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: